These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 6692384)
1. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Chlebowski RT; Heber D; Richardson B; Block JB Cancer Res; 1984 Feb; 44(2):857-61. PubMed ID: 6692384 [TBL] [Abstract][Full Text] [Related]
2. Glucose metabolism in cachectic patients with colorectal cancer. Holroyde CP; Skutches CL; Boden G; Reichard GA Cancer Res; 1984 Dec; 44(12 Pt 1):5910-3. PubMed ID: 6388829 [TBL] [Abstract][Full Text] [Related]
3. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. Fearon KC; Barber MD; Moses AG; Ahmedzai SH; Taylor GS; Tisdale MJ; Murray GD J Clin Oncol; 2006 Jul; 24(21):3401-7. PubMed ID: 16849754 [TBL] [Abstract][Full Text] [Related]
4. Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Chlebowski RT; Bulcavage L; Grosvenor M; Tsunokai R; Block JB; Heber D; Scrooc M; Chlebowski JS; Chi J; Oktay E Cancer; 1987 Feb; 59(3):406-10. PubMed ID: 3791153 [TBL] [Abstract][Full Text] [Related]
5. Hydrazine sulfate: a current perspective. Gold J Nutr Cancer; 1987; 9(2-3):59-66. PubMed ID: 3104888 [TBL] [Abstract][Full Text] [Related]
6. Anabolic profiles in late-stage cancer patients responsive to hydrazine sulfate. Gold J Nutr Cancer; 1981; 3(1):13-9. PubMed ID: 7050921 [TBL] [Abstract][Full Text] [Related]
7. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. ; Strasser F; Luftner D; Possinger K; Ernst G; Ruhstaller T; Meissner W; Ko YD; Schnelle M; Reif M; Cerny T J Clin Oncol; 2006 Jul; 24(21):3394-400. PubMed ID: 16849753 [TBL] [Abstract][Full Text] [Related]
8. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Lundholm K; Körner U; Gunnebo L; Sixt-Ammilon P; Fouladiun M; Daneryd P; Bosaeus I Clin Cancer Res; 2007 May; 13(9):2699-706. PubMed ID: 17473202 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Bruera E; Ernst S; Hagen N; Spachynski K; Belzile M; Hanson J; Summers N; Brown B; Dulude H; Gallant G Cancer Prev Control; 1998 Apr; 2(2):74-8. PubMed ID: 9765767 [TBL] [Abstract][Full Text] [Related]
10. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Simons JP; Schols AM; Hoefnagels JM; Westerterp KR; ten Velde GP; Wouters EF Cancer; 1998 Feb; 82(3):553-60. PubMed ID: 9452274 [TBL] [Abstract][Full Text] [Related]
11. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Pei D; Hsieh CH; Hung YJ; Li JC; Lee CH; Kuo SW Metabolism; 2006 Jul; 55(7):923-7. PubMed ID: 16784965 [TBL] [Abstract][Full Text] [Related]
12. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice. Marsman D Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194 [TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F; Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356 [TBL] [Abstract][Full Text] [Related]
14. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Sorge J; Sittl R Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693 [TBL] [Abstract][Full Text] [Related]
15. Current pharmacological management of anorexia in cancer patients. Bruera E Oncology (Williston Park); 1992 Jan; 6(1):125-30; discussion 132, 137. PubMed ID: 1531597 [TBL] [Abstract][Full Text] [Related]
16. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Fasano CJ; O'Malley G; Dominici P; Aguilera E; Latta DR Ann Emerg Med; 2008 Apr; 51(4):400-6. PubMed ID: 17764782 [TBL] [Abstract][Full Text] [Related]
17. Pathophysiology of cancer cachexia: current understanding and areas for future research. DeWys WD Cancer Res; 1982; 42(2 Suppl):721s-726s. PubMed ID: 7055813 [TBL] [Abstract][Full Text] [Related]
18. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Dujovne CA; Zavoral JH; Rowe E; Mendel CM; Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363 [TBL] [Abstract][Full Text] [Related]
19. Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure. Fliser D; Rett K; Hübinger A; Ritz E Nephrol Dial Transplant; 1995; 10(5):643-7. PubMed ID: 7566576 [TBL] [Abstract][Full Text] [Related]
20. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Daneryd P; Svanberg E; Körner U; Lindholm E; Sandström R; Brevinge H; Pettersson C; Bosaeus I; Lundholm K Cancer Res; 1998 Dec; 58(23):5374-9. PubMed ID: 9850068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]